康龙化成(03759)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03759 康龙化成

未开盘 09-28 16:08:28

30.060

-0.320

-1.05%

最高30.960	最低29.600	成交量394.79万
今开30.380	昨收30.380	日振幅4.48%
总市值551.60亿	流通市值107.61亿	总股本18.35亿
成交额1.19亿	换手率1.10%	流通股本3.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03759","market":"HK","secType":"STK","nameCN":"康龙化成","latestPrice":30.06,"timestamp":1790582908007,"preClose":30.38,"halted":0,"volume":3947945,"delay":0,"changeRate":-0.01053324555628704,"floatShares":358000000,"shares":1835000000,"eps":1.0982252447673142,"marketStatus":"未开盘","change":-0.32,"latestTime":"09-28 16:08:28","open":30.38,"high":30.96,"low":29.6,"amount":118568114,"amplitude":0.044766,"askPrice":30.06,"askSize":87000,"bidPrice":30.02,"bidSize":900,"shortable":3,"etf":0,"ttmEps":1.1101311615856528,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790645400000},"marketStatusCode":0,"adr":0,"listingDate":1574870400000,"exchange":"SEHK","adjPreClose":30.38,"dividendRate":0.007776,"openAndCloseTimeList":[[1790559000000,1790568000000],[1790571600000,1790582400000]],"volumeRatio":0.7182774912583197,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"300759","market":"SZ","secType":"STK","nameCN":"康龙化成","latestPrice":43.13,"timestamp":1790578800000,"preClose":43.5,"halted":0,"volume":33458500,"delay":0,"premium":"-40.39"}},"requestUrl":"/m/hq/s/03759","defaultTab":"news","newsList":[{"id":"2669607684","title":"摩根大通减持康龙化成(03759)约112.48万股 每股作价约30.37港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669607684","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669607684?lang=zh_cn&edition=full","pubTime":"2026-09-24 20:10","pubTimestamp":1790251848,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，9月21日，摩根大通减持康龙化成(03759)112.4839万股，每股作价30.3712港元，总金额约为3416.27万港元。减持后最新持股数目约为5322.35万股，最新持股比例为14.78%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500716.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","PGF","BK1576","EWH","300759","03759","BK0216","BK4582"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136729780","title":"康龙化成：BNP PARIBAS SA增持，好仓比例升至5.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=1136729780","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136729780?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:24","pubTimestamp":1790241854,"startTime":"0","endTime":"0","summary":"BNP PARIBAS SA于2026年9月21日通过取得股份保证权益的方式（因可换股债券相关衍生交易）增持康龙化成H股股份。该笔交易并非在联交所公开市场直接买卖，属股份保证权益取得。BNP PARIBAS SA此次增持前持有康龙化成好仓1567.47万股，占比4.38%；增持后持股量为1900.46万股，好仓比例升至5.31%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03759"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102669700","title":"康龙化成2026年中期营收75.95亿元，经调整净利润9.09亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1102669700","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102669700?lang=zh_cn&edition=full","pubTime":"2026-09-23 17:37","pubTimestamp":1790156250,"startTime":"0","endTime":"0","summary":"2026年上半年，康龙化成实现营收75.95亿元，同比增长17.9%；同期经调整净利润为9.09亿元，同比增长20.3%。同期毛利为24.75亿元，同比增长13.9%，经营活动现金流净额为10.85亿元，同比下降23.0%。本期销售及分销费用1.69亿元，同比增加18.6%；行政开支9.95亿元，同比提高17.2%；研发成本2.96亿元，同比增长18.1%。公司预计2026年全年收入将同比增长15%至20%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"康龙化成2026年中期营收75.95亿元，经调整净利润9.09亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03759"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669045431","title":"康龙化成（300759）披露实际控制人一致行动人部分股份解除质押公告，9月23日股价上涨1.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669045431","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669045431?lang=zh_cn&edition=full","pubTime":"2026-09-23 17:28","pubTimestamp":1790155732,"startTime":"0","endTime":"0","summary":"近日，康龙化成（北京）新药技术股份有限公司发布关于公司实际控制人的一致行动人部分股份解除质押的公告。本次解除质押后，龙泰康质押股份由12,780,000股减少至10,610,000股。截至公告披露日，实际控制人及其一致行动人所持股份不存在被冻结情况，所质押股份无平仓风险，不会导致公司实际控制权变更，对公司生产经营和公司治理无重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300029815.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03759","BK1576","BK1141","300759","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669510430","title":"摩根大通在康龙化成的H股好仓比例下降0.39%至15.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669510430","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669510430?lang=zh_cn&edition=full","pubTime":"2026-09-23 17:17","pubTimestamp":1790155020,"startTime":"0","endTime":"0","summary":"南财智讯9月23日电，香港交易所披露信息显示，JPMorganChase&Co.（摩根大通）在康龙化成的H股好仓（L）比例于9月18日从15.48%下降至15.09%。同时淡仓（S）比例从5.14%降至4.74%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609233882504162.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609233882504162.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["300759","BK1576","BK0216","03759","BK1141","PGF","BK4582"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188227323","title":"创新药概念走高，云顶新耀、药明巨诺-B涨逾5%，金斯瑞生物科技涨逾4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188227323","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188227323?lang=zh_cn&edition=full","pubTime":"2026-09-23 11:01","pubTimestamp":1790132509,"startTime":"0","endTime":"0","summary":"9月23日，创新药概念走高，云顶新耀、药明巨诺-B涨逾5%，金斯瑞生物科技涨逾4%，康方生物、诺诚健华涨逾3%，基石药业涨逾2%，百济神州、药明生物、君实生物涨逾1%，信达生物跟涨。9月12-15日2026年世界肺癌大会召开，多项中国创新药临床数据集中亮相，康方生物依沃西单药OS数据、B7H3 ADC等成为焦点；与此同时，2026年国家医保目录谈判收官，商保创新药目录同步推进，支付端改革预期升温，\"出海商业化+支付改善\"的产业逻辑持续强化。","market":"hk","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03759","09606","01801","03347","06606","02268","09995","02137","09688","06622","02359","06618","00241","06996","02269","06978","09966","01672"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1149825428","title":"异动解读｜康龙化成盘中上涨4.16%，CRO板块延续强势叠加多家投行上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1149825428","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149825428?lang=zh_cn&edition=full","pubTime":"2026-09-23 10:11","pubTimestamp":1790129494,"startTime":"0","endTime":"0","summary":"9月23日，康龙化成盘中上涨4.16%，报31.52港元，成交额5114.14万港元。消息面上，CRO板块近日持续走强，多重利好共振推升行情。机构层面，高盛给予康龙化成\"买入\"评级，大和、美银、大摩分别上调目标价至38.5、38.4、35.6港元。此外，公司实际控制人一致行动人龙泰康于9月21日解除217万股质押，摩根大通此前增持公司H股至17.16%，外资持续加仓释放积极信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康龙化成盘中上涨，CRO强势获多家投行看好","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03759"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136681056","title":"康龙化成03759：实际控制人一致行动人解除217万股质押","url":"https://stock-news.laohu8.com/highlight/detail?id=1136681056","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136681056?lang=zh_cn&edition=full","pubTime":"2026-09-22 17:41","pubTimestamp":1790070109,"startTime":"0","endTime":"0","summary":"2026年9月22日，康龙化成（北京）新药技术股份有限公司发布公告称，公司实际控制人的一致行动人宁波龙泰康投资管理有限公司已于2026年9月21日解除部分股份质押，涉及股份2,170,000股，占其所持股份的5.41%，占公司总股本的0.12%。本次解除质押的股份最初于2024年12月25日质押，质权人为中信证券股份有限公司。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03759"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669117114","title":"康龙化成：实际控制人的一致行动人龙泰康解除质押217万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669117114","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669117114?lang=zh_cn&edition=full","pubTime":"2026-09-22 16:35","pubTimestamp":1790066100,"startTime":"0","endTime":"0","summary":"南财智讯9月22日电，康龙化成公告，公司实际控制人的一致行动人宁波龙泰康投资管理有限公司（简称“龙泰康”）将其持有的公司217万股股份解除质押，占其所持股份比例的5.41%，占公司总股本的0.12%，质权人为中信证券股份有限公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609223881272538.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609223881272538.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0216","03759","BK1141","300759","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177131900","title":"异动解读｜康龙化成盘中上涨3.15%，CRO板块延续强势叠加多家投行上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1177131900","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177131900?lang=zh_cn&edition=full","pubTime":"2026-09-22 10:33","pubTimestamp":1790044394,"startTime":"0","endTime":"0","summary":"9月22日，康龙化成盘中上涨3.15%，报31.44港元，成交额1.11亿港元。消息面上，CRO板块近日持续走强，诺和诺德与Anthropic达成AI制药合作，国内创新药对外授权交易总额突破1200亿美元，药企研发资金趋于充裕，CRO企业在手订单呈\"量价齐升\"态势。此外，十部门近期联合发文支持创新药发展，政策红利持续释放。高盛明确看好中国CRO/CDMO行业复苏并给予康龙化成\"买入\"评级，大和、美银、大摩分别上调目标价至38.5、38.4、35.6港元。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康龙化成盘中上涨，CRO回暖获投行看好","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03759"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669139506","title":"医药外包概念盘初走高 昭衍新药（06127）涨6.14% 机构指CXO为医药行业中最亮眼板块之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2669139506","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669139506?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:10","pubTimestamp":1789956632,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医药外包概念盘初走高，截至发稿，昭衍新药（06127）涨6.14%，药明生物（02269）涨4.97%，金斯瑞生物科技（01548）涨4.47%，维亚生物（01873）涨3.75%，药明康德（02359）涨3.40%，泰格医药（03347）涨2.52%，康龙化成（03759）涨2.64%。中邮证券研究指，2026中报看，CXO行业是医药行业中最亮眼板块之一。数据上看，CDMO龙头、安评及临床CRO是三条景气主线。估值上看，CDMO龙头公司按2027PE仍处于合理区间，CRO环节公司报表仍处修复阶段，新签高毛利订单待转化，因此表观估值较高，但预计随着订单的逐渐周转快速消化。","market":"other","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992050","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1794554557.SGD","LU0348766576.USD","LU2242644610.SGD","BK1589","LU1242518857.USD","BK1141","LU3063872942.SGD","LU1880383366.USD","LU0348825331.USD","LU0516423091.SGD","LU2125910500.SGD","02269","01548","HK0000320223.HKD","02359","BK1515","KURE","BK1610","LU0307460666.USD","LU0359201612.USD","LU0588546209.SGD","LU0456846285.SGD","603127","LU0516422366.SGD","LU0516422440.USD","159938","LU0516422952.EUR","09939","SG9999002463.SGD","HK0000306701.USD","LU0181495838.USD","CXO","03759","LU0029874905.USD","03347","LU0051755006.USD","LU0052750758.USD","BK1583","LU0320764599.SGD","LU0561508036.HKD","06127","LU0516423174.USD","WX","01873","LU0029874061.USD","LU0359202008.SGD","LU0540923850.HKD","BK1161","LU0039217434.USD","LU0043850808.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124128782","title":"异动解读｜康龙化成盘中上涨3.25%，CRO板块全线走强叠加AI制药催化及政策利好延续强势","url":"https://stock-news.laohu8.com/highlight/detail?id=1124128782","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124128782?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:57","pubTimestamp":1789955874,"startTime":"0","endTime":"0","summary":"9月21日，康龙化成盘中上涨3.25%，报30.48港元，成交额9507.41万港元。消息面上，CRO板块近日持续走强，诺和诺德与Anthropic达成AI制药合作，国内创新药对外授权交易总额突破1200亿美元，药企研发资金趋于充裕，CRO企业在手订单呈\"量价齐升\"态势。此外，十部门近期联合发文支持创新药发展，政策红利持续释放。高盛明确看好中国CRO/CDMO行业复苏并给予康龙化成\"买入\"评级，大和、美银、大摩分别上调目标价至38.5、38.4、35.6港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"康龙化成上涨，CRO全线走强叠加AI制药催化","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03759"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668947509","title":"康龙化成(03759.HK)授出合共约353.36万股H股奖励","url":"https://stock-news.laohu8.com/highlight/detail?id=2668947509","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668947509?lang=zh_cn&edition=full","pubTime":"2026-09-18 18:21","pubTimestamp":1789726914,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1141","03759","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151141724","title":"康龙化成(03759)授出合计353.36万股H股奖励股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1151141724","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151141724?lang=zh_cn&edition=full","pubTime":"2026-09-18 18:20","pubTimestamp":1789726844,"startTime":"0","endTime":"0","summary":"2026年9月18日，康龙化成（北京）新药技术股份有限公司公告，根据《2025年H股奖励信托计划》及《2026年H股奖励信托计划》分别向307名员工授出合计3,533,634股H股奖励，授予价不适用，授予日H股收市价为每股29.52港元。其中，2025年H股计划向221名合资格员工授出2,042,159股H股；2026年H股计划向86名合资格员工授出1,491,475股H股。授出后，2025年H股计划的剩余可授出额度为42,324股H股，2026年H股计划的剩余可授出额度为26,508,525股H股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03759"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125024076","title":"异动解读｜康龙化成盘中上涨3.61%，CRO板块全线走强叠加AI制药催化延续强势","url":"https://stock-news.laohu8.com/highlight/detail?id=1125024076","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125024076?lang=zh_cn&edition=full","pubTime":"2026-09-18 09:57","pubTimestamp":1789696667,"startTime":"0","endTime":"0","summary":"9月18日，康龙化成盘中上涨3.61%，报30.48港元，成交额4777.7万港元。消息面上，CRO板块连日全线走强，诺和诺德与Anthropic达成AI制药合作，将使用Claude Science平台助力新药研发，叠加国内创新药出海步伐加速，对外授权交易总额已突破1200亿美元，药企研发资金趋于充裕，CRO企业在手订单呈\"量价齐升\"态势。高盛此前明确看好中国CRO/CDMO行业复苏并给予康龙化成\"买入\"评级，大和、美银、大摩分别上调目标价至38.5、38.4、35.6港元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康龙化成盘中走强，CRO订单量价齐升","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03759"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175025641","title":"康龙化成：摩根大通减持，好仓比例降至15.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1175025641","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175025641?lang=zh_cn&edition=full","pubTime":"2026-09-17 17:12","pubTimestamp":1789636347,"startTime":"0","endTime":"0","summary":"摩根大通于2026年9月14日以每股均价28.9689港元场外解除股份保证权益，涉及康龙化成（03759）H股489.89万股，涉资约1.42亿港元。该笔为场外交易（代价性质：现金），未经联交所公开市场撮合，不属二级市场直接买卖。摩根大通此次减持前持有康龙化成好仓6177.88万股，占比17.16%；减持后持股量为5687.99万股，好仓比例降至15.8%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03759"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668993356","title":"【千亿药企龙头深度拆解】药明系：上市主体的资本与产业实验","url":"https://stock-news.laohu8.com/highlight/detail?id=2668993356","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668993356?lang=zh_cn&edition=full","pubTime":"2026-09-17 16:05","pubTimestamp":1789632300,"startTime":"0","endTime":"0","summary":"李革联合私募基金，以约33亿美元将药明康德从纽交所私有化退市。退市不是终点，而是重新切割业务、分批资本化的起点。药明生物是从药明康德大分子板块独立出来的公司，主业是大分子生物药CRDMO，包括抗体、双抗、融合蛋白、疫苗等生物药的研发与生产。药明合联的价值，正是依托药明生物的大分子平台、药明康德/合全药业的小分子平台，完成偶联、制剂与规模化生产，实现整套链条协同。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650514222&idx=1&sn=a5888f47603d14bfee478c846e35b8f0&chksm=f321e62ca04295728bbd6dcb9b1f75e4de3b57897423b59c2fa696ad13c6ef57c2cb3924a020&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["LU2045819591.USD","LU2097828557.USD","LU2125910500.SGD","LU0320764243.SGD","LU0856984785.SGD","LU1794554557.SGD","03347","LU0819121731.USD","02268","LU0359202008.SGD","LU0348827113.USD","LU0149534421.HKD","LU0502904849.HKD","LU0128526141.USD","LU0244354667.USD","LU0039217434.USD","03759","LU1023057109.AUD","LU1188198961.HKD","BK1583","LU2039709279.SGD","HK0000165453.HKD","LU0708995583.HKD","LU0029874061.USD","LU0417516738.SGD","LU0823426480.USD","LU0327786744.USD","LU0540923850.HKD","BK1141","LU0348766576.USD","LU0128522744.USD","01801","BK1191","02359","LU2242644610.SGD","01276","LU0516422440.USD","02126","LU1880383366.USD","IE00B0JY6N72.USD","01875","LU1046422090.SGD","02269","LU0463099449.HKD","LU0588546209.SGD","LU2097828631.EUR","LU0469268626.HKD","LU1720050803.USD","LU0326950275.SGD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177817300","title":"康龙化成：摩根大通增持，好仓比例升至17.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=1177817300","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177817300?lang=zh_cn&edition=full","pubTime":"2026-09-16 17:23","pubTimestamp":1789550599,"startTime":"0","endTime":"0","summary":"摩根大通于2026年9月11日通过取得股份保证权益的方式增持康龙化成H股171.68万股，涉及金额约4708.79万港元，每股均价27.4278港元，该笔交易属场外交易（代价性质：现金），未经联交所公开市场撮合，不属二级市场直接买卖。摩根大通此次增持前持有康龙化成好仓6006.20万股，占比16.68%；增持后持股量为6177.88万股，好仓比例升至17.16%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03759"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162878126","title":"异动解读｜康龙化成盘中上涨3.26%，CRO板块持续走强多家投行上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1162878126","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162878126?lang=zh_cn&edition=full","pubTime":"2026-09-16 09:36","pubTimestamp":1789522602,"startTime":"0","endTime":"0","summary":"9月16日，康龙化成盘中上涨3.26%，报29.78港元，成交额1812.76万港元。消息面上，CRO/CDMO板块延续强势，药明康德中报业绩大幅超预期并上调全年指引，持续验证行业高景气。康龙化成自身上半年营收75.95亿元，同比增长17.9%，其中CDMO收入同比增长32.8%，管理层将全年收入增长指引由12%-18%上调至15%-20%。近期大和、美银、大摩分别上调公司目标价至38.5、38.4、35.6港元，均维持买入或增持评级。此外，摩根大通、摩根士丹利、花旗集团近期均增持公司H股。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康龙化成盘中走强，多家投行上调目标价","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03759"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667654184","title":"摩根士丹利在康龙化成的H股好仓比例下降0.09%至6.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667654184","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667654184?lang=zh_cn&edition=full","pubTime":"2026-09-14 17:22","pubTimestamp":1789377752,"startTime":"0","endTime":"0","summary":"南财智讯9月14日电，香港交易所披露信息显示，MorganStanley（摩根士丹利）在康龙化成的H股好仓（L）比例于9月9日从6.78%下降至6.69%。同时淡仓（S）比例从3.98%升至4.02%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609143873500286.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609143873500286.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0216","300759","BK1576","03759","BK1141"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pharmaron.com","stockEarnings":[{"period":"1week","weight":-0.0138},{"period":"1month","weight":0.0211},{"period":"3month","weight":0.6657},{"period":"6month","weight":0.4559},{"period":"1year","weight":0.1819},{"period":"ytd","weight":0.5518}],"compareEarnings":[{"period":"1week","weight":-0.016},{"period":"1month","weight":-0.0368},{"period":"3month","weight":0.077},{"period":"6month","weight":-0.0258},{"period":"1year","weight":-0.0569},{"period":"ytd","weight":-0.0385}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康龙化成（北京）新药技术股份有限公司是一家主要从事医药研发的中国公司。该公司运营五个分部。实验室服务分部主要包括实验室化学和生物科学服务，服务项目涵盖小分子化学药、寡核苷酸、多肽、抗体、抗体偶联药物和细胞与基因治疗产品等。化学和制剂工艺开发及生产服务分部包括原料药工艺开发及生产以及预制剂、制剂开发。临床研究服务分部包括国外临床研究服务和国内临床研究服务。大分子和细胞与基因治疗服务分部包括大分子药物发现及开发与生产服务和细胞与基因治疗实验室及基因治疗药物开发与生产服务。该公司还通过其他分部开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":-0.020006},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.034007},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.039454},{"month":4,"riseRate":0.857143,"avgChangeRate":0.052246},{"month":5,"riseRate":0.571429,"avgChangeRate":-0.006682},{"month":6,"riseRate":0.714286,"avgChangeRate":0.071007},{"month":7,"riseRate":0.714286,"avgChangeRate":0.108056},{"month":8,"riseRate":0.428571,"avgChangeRate":0.003953},{"month":9,"riseRate":0.714286,"avgChangeRate":0.125495},{"month":10,"riseRate":0.5,"avgChangeRate":-0.053123},{"month":11,"riseRate":0.333333,"avgChangeRate":0.036146},{"month":12,"riseRate":0.571429,"avgChangeRate":0.025859}],"exchange":"SEHK","name":"康龙化成","nameEN":"PHARMARON"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康龙化成(03759)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康龙化成(03759)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康龙化成,03759,康龙化成股票,康龙化成股票老虎,康龙化成股票老虎国际,康龙化成行情,康龙化成股票行情,康龙化成股价,康龙化成股市,康龙化成股票价格,康龙化成股票交易,康龙化成股票购买,康龙化成股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康龙化成(03759)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康龙化成(03759)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}